辛伐他汀联合厄贝沙坦对糖尿病肾病患者AOPP、ICAM-1、IL-1β水平的影响

Effects of simvastatin and irbesartan on AOPP,ICAM-1 and IL-1β in patients with diabetic nephropathy

目的探讨辛伐他汀联合厄贝沙坦对糖尿病肾病患者晚期氧化蛋白产物(AOPP)、细胞间黏附分子-1(ICAM-1)、白细胞介素1β(IL-1β)水平的影响。方法于2014年5月至2015年5月选择糖尿病肾病患者60例,以抽签法平均分为观察组和对照组,对照组使用厄贝沙坦治疗,观察组在对照组的基础上加用辛伐他汀。观察两组患者治疗前后血压、血脂、肾功能、AOPP、ICAM-1、IL-1β水平变化情况,并比较疗效。结果治疗后,观察组总胆固醇、三酰甘油、血肌酐、血尿素氮、尿清蛋白排泄率、AOPP、ICAM-1及IL-1β水平均低于对照组(P<0.05)。观察组临床疗效总有效率为96.67%,高于对照组(70.00%,P<0.05)。结论辛伐他汀联合厄贝沙坦对糖尿病肾病患者疗效显著,可有效降低患者体内AOPP、ICAM-1、IL-1β水平,值得在临床推广应用。

Objective To investigate the effects of simvastatin combined with irbesartan on levels of advanced oxidation protein products（AOPP） ,intercellular adhesion molecul‐1（ICAM‐1） and interleukin‐1β（IL‐1β） in patients with diabetic nephropathy .Meth‐ods From May 2014 to May 2015 ,60 cases of diabetic nephropathy patients were divided into observation group and control group .The control group was treated with irbesartan ,and the observation group was treated with simvastatin combined with irbe‐sartan .Blood pressure ,blood lipid ,renal function ,ICAM‐1 ,IL‐1β and AOPP were detected before and after treatment in the two groups .Results After treatment ,levels of total cholesterol ,triacylglycerol ,serum creatinine ,blood urea nitrogen ,urine albumin ex‐cretion rate ,ICAM‐1 ,IL‐1βand AOPP in observation group were significantly lower than the control group （P〈0 .05） .The clinical efficacy of the observation group was 96 .67% ,which was higher than the 70 .00% of the control group（P〈0 .05） .Conclusion Simvastatin combined with irbesartan could be with significant therapeutic effect in diabetic nephropathy patients ,and effectively re‐duce the levels of AOPP ,ICAM‐1 ,IL‐1β,which might be worth in clinical application .